Optimal Management Strategies for Chronic Iron Overload

Overview

Journal Drugs

Specialty Pharmacology

Date 2007 Mar 28

PMID 17385941

Citations 7

Authors

James C Barton

Affiliations

Soon will be listed here.

Abstract

Iron overload is characterised by excessive iron deposition and consequent injury and dysfunction of target organs, especially the heart, liver, anterior pituitary, pancreas and joints. Iron overload disorders are common worldwide and occur in most major race/ethnicity groups. Physiological mechanisms to excrete iron are very limited. Thus, all patients with iron overload need safe and effective treatment that is compatible with their co-existing medical conditions. Treatments for iron overload include phlebotomy and erythrocytapheresis that remove iron predominantly as haemoglobin, and chelation therapy with drugs that bind excess iron selectively and increase its excretion. The most important potential benefits of therapy are preventing deaths due to cardiac siderosis and hepatic cirrhosis. Preventing iron-related injury to endocrine organs is critical in children. Successful treatment or prevention of iron overload increases quality of life and survival in many patients. This article characterises the major categories of iron overload disorders, tabulates methods to evaluate and treat iron overload, and describes treatment options for iron overload disorders. Research needed to advance knowledge about treatment of iron overload is proposed.

Citing Articles

Effect of tannic acid-templated mesoporous silica nanoparticles on iron-induced oxidative stress and liver toxicity in rats.

Javdani H, Etemad L, Moshiri M, Zarban A, Hanafi-Bojd M Toxicol Rep. 2021; 8:1721-1728.

PMID: 34692422 PMC: 8512627. DOI: 10.1016/j.toxrep.2021.09.005.

Glycoside rich fraction from Spondias pinnata bark ameliorate iron overload induced oxidative stress and hepatic damage in Swiss albino mice.

Chaudhuri D, Ghate N, Panja S, Basu T, Shendge A, Mandal N BMC Complement Altern Med. 2016; 16:262.

PMID: 27472924 PMC: 4966786. DOI: 10.1186/s12906-016-1244-4.

Early Cardiac Iron Overload in a Child on Treatment of Acute Lymphoblastic Leukemia.

Reitman A, Coates T, Freyer D Pediatrics. 2015; 136(3):e697-700.

PMID: 26283784 PMC: 7514881. DOI: 10.1542/peds.2014-3770.

Synthetic and natural iron chelators: therapeutic potential and clinical use.

Hatcher H, Singh R, Torti F, Torti S Future Med Chem. 2011; 1(9):1643-70.

PMID: 21425984 PMC: 3821171. DOI: 10.4155/fmc.09.121.

Iron chelation therapy in thalassemia syndromes.

Cianciulli P Mediterr J Hematol Infect Dis. 2011; 1(1):e2009034.

PMID: 21415999 PMC: 3033168. DOI: 10.4084/MJHID.2009.034.

References

Kushner J, Porter J, Olivieri N . Secondary iron overload. Hematology Am Soc Hematol Educ Program. 2001; :47-61. DOI: 10.1182/asheducation-2001.1.47. View

Kohan A, Niborski R, Daruich J, Rey J, Bastos F, Amerise G . Erythrocytapheresis with recombinant human erythropoietin in hereditary hemochromatosis therapy: a new alternative. Vox Sang. 2000; 79(1):40-5. DOI: 10.1159/000031204. View

Shalev O, Repka T, Goldfarb A, Grinberg L, Abrahamov A, Olivieri N . Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. Blood. 1995; 86(5):2008-13. View

Jensen P, Jensen I, Ellegaard J . Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome. Br J Haematol. 1992; 80(1):121-4. DOI: 10.1111/j.1365-2141.1992.tb06411.x. View

Butensky E, Fischer R, Hudes M, Schumacher L, Williams R, Moyer T . Variability in hepatic iron concentration in percutaneous needle biopsy specimens from patients with transfusional hemosiderosis. Am J Clin Pathol. 2005; 123(1):146-52. DOI: 10.1309/puuxegxdlh26nxa2. View

Kolnagou A, Kontoghiorghes G . Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators. Hemoglobin. 2006; 30(2):239-49. DOI: 10.1080/03630260600642567. View

Greenberg P, Baer M, Bennett J, Bloomfield C, de Castro C, Deeg H . Myelodysplastic syndromes clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006; 4(1):58-77. View

Aldouri M, Wonke B, Hoffbrand A, Flynn D, Ward S, Agnew J . High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol. 1990; 84(3):113-7. DOI: 10.1159/000205046. View

Olivieri N, Brittenham G, Matsui D, Berkovitch M, Blendis L, Cameron R . Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med. 1995; 332(14):918-22. DOI: 10.1056/NEJM199504063321404. View

10.

Donovan J, Plone M, Dagher R, Bree M, Marquis J . Preclinical and clinical development of deferitrin, a novel, orally available iron chelator. Ann N Y Acad Sci. 2005; 1054:492-4. DOI: 10.1196/annals.1345.071. View

11.

Cohen A, Galanello R, Piga A, De Sanctis V, Tricta F . Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003; 102(5):1583-7. DOI: 10.1182/blood-2002-10-3280. View

12.

Kaltwasser J, Werner E, Schalk K, Hansen C, Gottschalk R, Seidl C . Clinical trial on the effect of regular tea drinking on iron accumulation in genetic haemochromatosis. Gut. 1998; 43(5):699-704. PMC: 1727318. DOI: 10.1136/gut.43.5.699. View

13.

Glickstein H, El R, Shvartsman M, Cabantchik Z . Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood. 2005; 106(9):3242-50. DOI: 10.1182/blood-2005-02-0460. View

14.

Leardi A, Caraglia M, Selleri C, Pepe S, Pizzi C, Notaro R . Desferioxamine increases iron depletion and apoptosis induced by ara-C of human myeloid leukaemic cells. Br J Haematol. 1998; 102(3):746-52. DOI: 10.1046/j.1365-2141.1998.00834.x. View

15.

Hannuksela J, Savolainen E, Koistinen P, Parkkila S . Prevalence of HFE genotypes, C282Y and H63D, in patients with hematologic disorders. Haematologica. 2002; 87(2):131-5. View

16.

Borgna-Pignatti C, Cappellini M, De Stefano P, Del Vecchio G, Forni G, Gamberini M . Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2005; 107(9):3733-7. DOI: 10.1182/blood-2005-07-2933. View

17.

Adams D, Schultz W, Ware R, Kinney T . Erythrocytapheresis can reduce iron overload and prevent the need for chelation therapy in chronically transfused pediatric patients. J Pediatr Hematol Oncol. 1996; 18(1):46-50. DOI: 10.1097/00043426-199602000-00009. View

18.

Kersten M, Lange R, Smeets M, Vreugdenhil G, Roozendaal K, Lameijer W . Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. Ann Hematol. 1996; 73(5):247-52. DOI: 10.1007/s002770050236. View

19.

Cohen A, Schwartz E . Excretion of iron in response to deferoxamine in sickle cell anemia. J Pediatr. 1978; 92(4):659-62. DOI: 10.1016/s0022-3476(78)80317-5. View

20.

Anderson L, Westwood M, Prescott E, Walker J, Pennell D, Wonke B . Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine. Acta Haematol. 2006; 115(1-2):106-8. DOI: 10.1159/000089475. View